Infantile Hemangioma: Benefits to Starting Propranolol Early Infantile Hemangioma: Benefits to Starting Propranolol Early
The findings are from a post-hoc analysis of phase 2 and 3 clinical trial data from the study that showed propranolol was effective in the treatment of infantile hemangioma.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2023 Category: Consumer Health News Tags: Dermatology News Source Type: news
Seizures and irreversible cardiogenic shock following propranolol poisoning: report of 2 cases and literature review - Sharifpour A, Sadeghi M, Zakariae Z, Soleymani M.
Propranolol, a β-blocker (BB), is one of the drugs that can be misused for suicide. The clinical manifestations of overdose can range from asymptomatic to neurological symptoms such as seizures and loss of consciousness, cardiac shock, and even death. Her... (Source: SafetyLit)
Source: SafetyLit - October 3, 2022 Category: International Medicine & Public Health Tags: Poisoning Source Type: news
Nadolol Noninferior to Propranolol for Infantile Hemangiomas: Study Nadolol Noninferior to Propranolol for Infantile Hemangiomas: Study
' Further studies are needed to prove superiority over propranolol, ' say the study authors.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 25, 2021 Category: Consumer Health News Tags: Pediatrics News Source Type: news
Nonselective Beta-blockers and HCC Risk Among Cirrhotic Patients Nonselective Beta-blockers and HCC Risk Among Cirrhotic Patients
Might nonselective beta-blockers such as carvedilol, nadolol, and propranolol decrease the risk of hepatocellular carcinoma among patients with cirrhosis?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 6, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Beta-Blocker May Improve Melanoma Treatment Response Beta-Blocker May Improve Melanoma Treatment Response
Response rates were high without dose-limiting toxicities in a small phase 1 study that evaluated the addition of propranolol to pembrolizumab in treatment-naive patients with metastatic melanoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Cancer treatment could be replicated for COVID-19
Beta-blockers could potentially be used to treat COVID-19, according to a new international study by Italian and Australian scientists.
University of South Australia cancer researcher, Dr Nirmal Robinson, working with a team in Naples, has found evidence in animal models that the beta-blocker Propranolol helps suppress the spread of cancer in the lung which has an inflammatory profile very similar to COVID-19. (Source: World Pharma News)
Source: World Pharma News - November 3, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
AstraZeneca completes divestment agreement with Atnahs Pharma for established hypertension medicines
AstraZeneca today announced that it has completed the previously communicated agreement with Atnahs Pharma (Atnahs) to divest its global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination). (Source: World Pharma News)
Source: World Pharma News - March 2, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Potential under-recognised risk of harm from the use of propranolol
The Healthcare safety investigation branch (HSIB) hasconducted a patient safety investigation that explores the under recognised toxicity of propranolol in overdose... (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - February 20, 2020 Category: Drugs & Pharmacology Source Type: news
AstraZeneca divests rights to established hypertension medicines
AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to Atnahs Pharma (Atnahs). (Source: World Pharma News)
Source: World Pharma News - January 27, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
propranolol, Inderal, Inderal LA, Innopran XL
Title: propranolol, Inderal, Inderal LA, Innopran XLCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 7/5/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - July 5, 2019 Category: Cardiology Source Type: news
